Corcept Therapeutics Incorporated (NASDAQ:CORT) bio-pharma drug manufacturer will be discussing 3Q20 financial results with the investment community.on 3rd November 2020 at 5:00 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.corcept.com
Earnings Expectation
Corcept Therapeutics Incorporated is reporting third quarter financial results on Tuesday 3rd November 2020, after market close.
According to analysts surveyed by Thomson Reuters, CORT is expected to report 3Q20 income of $ 0.20 per share from revenue of $ 90.87 million.
For the full year, analysts anticipate top line of $ 366.22 million, while looking forward to income of $ 0.86 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 355.00 million ~ $ 375.00 million
Click Here For More Historical Outlooks Of Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushings syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat metastatic ovarian cancer, as well as in Phase I/II clinical trial for the treatment of solid tumors.
